A Comparison of 15% Azelaic Acid Gel and 0.75% Metronidazole Gel in the Topical Treatment of Papulopustular Rosacea: Results of a Randomized Trial

Archives of Dermatology

Volumn 139, Issue 11, 2003, Pages 1444-1450

  Elewski, Boni E ^a   Fleischer Jr , Alan B ^b   Pariser, David M ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; FINACEA; METRONIDAZOLE;

ADULT; AGED; ARTICLE; BURN; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; ERYTHEMA; FACE EDEMA; FEMALE; GEL; HUMAN; INSECT STING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PAPULOPUSTULAR ROSACEA; PHOTOALLERGY; PHOTOTOXICITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SKIN IRRITATION; SKIN TOXICITY; TELANGIECTASIA; TOXIC EPIDERMAL NECROLYSIS;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; GELS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OSMOLAR CONCENTRATION; PATIENT SATISFACTION; ROSACEA; TELANGIECTASIS; TREATMENT OUTCOME;

EID: 0242492116     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.11.1444     Document Type: Article

References (13)

1. Dahl MV. Pathogenesis of rosacea. Adv Dermatol. 2001;17:29-45.
2. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol 1994;130:359-362.
3. Zuber TJ. Rosacea. Prim Care. 2000;27:309-318.
4. Cohen AF, Tiemstra JD. Diagnosis and treatment of rosacea. J Am Board Fam Pract. 2002;15:214-217.
5. Plewig G, Kligman AM. Acne and Rosacea. 3rd ed. Berlin, Germany: Springer-Verlag; 2000:460.
6. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
7. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496.
8. Thiboutot DM. Acne and rosacea: new and emerging therapies. Dermatol Clin. 2000;18:63-71.
9. Bjerke R, Fyrand O, Graupe K, Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulopustular rosacea. Acta Derm Venereol. 1999;79:456-459.
10. Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat. 1993;4(suppl 1):S19-S22.
11. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40:961-965.
12. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
13. Passi S, Picardo M, Zompetta C, et al. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun. 1991;15:17-28.